Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea - Experience from 110 patients

Kihyun Kim, Seok Jin Kim, Verena Voelter, Cheolwon Suh, Sung Soo Yoon, Je Jung Lee, Jae Yong Kwak, Hun Mo Ryoo, Yang Soo Kim, Joon Ho Moon, Seong Kyu Park, Sung Hyun Kim, Yeung Chul Mun, Jin Seok Kim, Hyeon Seok Eom, Deog Yeon Jo, Hyun Jung Jun, Ki Hwan Kim, Jeong Ok Lee, Jae Hoon LeeChang Ki Min

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program. Lenalidomide has been approved for RRMM for several years in Europe and North America, but has not been accessible to Asian patients in the past. Between 2008 and 2012, 110 patients from 20 hospitals were enrolled. The overall response rate (ORR) was 43.6 % with 15.4 % of very good partial response (VGPR) or better. The median time to progression (TTP) in this heavily pretreated patient population was 8.0 months, and median overall survival (OS) was 23 months. Hematologic toxicities, fatigue, anorexia, and constipation were the most common adverse events. The number of previous treatment lines, previous exposure to thalidomide, refractoriness to thalidomide and bortezomib, pretreatment white blood cell count (WBC), platelet count, t(14;16), and 17p deletion were significant prognostic factors for TTP, and creatinine clearance, refractoriness to thalidomide and bortezomib, performance status, platelet count, and 17p deletion were significant for OS in univariate analysis. In multivariate analysis, WBC and platelet count were significant prognostic factors for TTP and performance status for OS. For Korean myeloma patients, lenalidomide showed considerable efficacy, and toxicities were comparable to the data published in Europe and North America.

Original languageEnglish
Pages (from-to)113-121
Number of pages9
JournalAnnals of Hematology
Volume93
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea - Experience from 110 patients'. Together they form a unique fingerprint.

  • Cite this

    Kim, K., Kim, S. J., Voelter, V., Suh, C., Yoon, S. S., Lee, J. J., Kwak, J. Y., Ryoo, H. M., Kim, Y. S., Moon, J. H., Park, S. K., Kim, S. H., Mun, Y. C., Kim, J. S., Eom, H. S., Jo, D. Y., Jun, H. J., Kim, K. H., Lee, J. O., ... Min, C. K. (2014). Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea - Experience from 110 patients. Annals of Hematology, 93(1), 113-121. https://doi.org/10.1007/s00277-013-1893-z